What does JD Pharma do?

JD Pharma is registered with the CBE as active in: Activiteiten van holdings. Private Limited, started on 5 October 2015, 1 establishment.

What is the address of JD Pharma?

The registered office of JD Pharma is located at Overleiestraat(Kor) 52, 8500 Kortrijk.

Is JD Pharma still active?

Yes. According to the CBE (30 October 2026) JD Pharma is active, legal situation “Normale toestand”, started on 5 October 2015.

Is JD Pharma registered on Peppol?

Yes, JD Pharma is registered on the Peppol network with ID 0208:0639894746.

What is the enterprise number of JD Pharma?

The enterprise number of JD Pharma is BE0639894746.

When was JD Pharma founded?

JD Pharma was founded on 5 October 2015.

Who are the directors of JD Pharma?

According to the 2025 annual accounts, the directors of JD Pharma are: Julie Dieusaert.

Is JD Pharma a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 5 October 2015; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did JD Pharma make in 2025?

JD Pharma posted a profit after taxes of € 48,565 in financial year 2025.

What is the revenue of JD Pharma?

As a small company, JD Pharma is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 136,528.

JD Pharma (Private Limited) - Kortrijk - BE0639894746

Dossier JD Pharma, printed on 30 October 2026 from databakkes.be/en/0639894746/jd-pharma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Tight liquidity NBB

Cash and receivables cover 15 % of short-term debt in 2025; threshold 65 %.

Financials

Financial year 2025

JD Pharma from Kortrijk, company number BE0639894746, closed financial year 2025 with a result of € 48,565 after tax. For that financial year JD Pharma recorded a gross margin of € 136,528 and equity of € 514,700. Compared with financial year 2024, the result moved from € 59,774 to € 48,565. The company is profitable. The buffer is growing. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on August 28, 2026.

What it is worth Growing

€ 514,700

▲ 10% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Healthy

€ 48,565

▼ 19% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 27,506

▲ 99% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € 496,100.

People and assets in 2025

Vehicles and equipment

€ 6,619

▼ 21% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 13 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 445,459

▲ 44% vs 2024

€ 35,222 is repaid this year. At this pace the long-term loan is gone in ≈ 13 years.

Owed to suppliers

€ 71,503

▲ € 69,348 vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 11,710

▼ 4% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 67,422 Gross margin 2022: € 67,422 First fiscal year in the series	€ 359,901 Gross margin 2023: € 359,901 ▲ € 292,479 vs 2022 (€ 67,422) Favourable step	€ 123,339 Gross margin 2024: € 123,339 ▼ 66% vs 2023 (€ 359,901) Unfavourable step	€ 136,528 Gross margin 2025: € 136,528 ▲ 11% vs 2024 (€ 123,339) Favourable step	▲ 11%
Profit after taxes	€ 33,557 Profit after taxes 2022: € 33,557 First fiscal year in the series	€ 221,286 Profit after taxes 2023: € 221,286 ▲ € 187,729 vs 2022 (€ 33,557) Favourable step	€ 59,774 Profit after taxes 2024: € 59,774 ▼ 73% vs 2023 (€ 221,286) Unfavourable step	€ 48,565 Profit after taxes 2025: € 48,565 ▼ 19% vs 2024 (€ 59,774) Unfavourable step	▼ 19%
Equity	€ 185,075 Equity 2022: € 185,075 First fiscal year in the series	€ 406,361 Equity 2023: € 406,361 ▲ 120% vs 2022 (€ 185,075) Favourable step	€ 466,135 Equity 2024: € 466,135 ▲ 15% vs 2023 (€ 406,361) Favourable step	€ 514,700 Equity 2025: € 514,700 ▲ 10% vs 2024 (€ 466,135) Favourable step	▲ 10%
Total debts	€ 951,046 Total debts 2022: € 951,046 First fiscal year in the series	€ 1,002,074 Total debts 2023: € 1,002,074 ▲ 5% vs 2022 (€ 951,046) Unfavourable step	€ 919,919 Total debts 2024: € 919,919 ▼ 8% vs 2023 (€ 1,002,074) Favourable step	€ 1,132,971 Total debts 2025: € 1,132,971 ▲ 23% vs 2024 (€ 919,919) Unfavourable step	▲ 23%
Cash	€ 45,506 Cash 2022: € 45,506 First fiscal year in the series	€ 14,904 Cash 2023: € 14,904 ▼ 67% vs 2022 (€ 45,506) Unfavourable step	€ 13,856 Cash 2024: € 13,856 ▼ 7% vs 2023 (€ 14,904) Unfavourable step	€ 27,506 Cash 2025: € 27,506 ▲ 99% vs 2024 (€ 13,856) Favourable step	▲ 99%
Land & buildings	€ 125,187 Land & buildings 2022: € 125,187 First fiscal year in the series	€ 422,318 Land & buildings 2023: € 422,318 ▲ 237% vs 2022 (€ 125,187) Unchanged	€ 397,303 Land & buildings 2024: € 397,303 ▼ 6% vs 2023 (€ 422,318) Unchanged	€ 570,944 Land & buildings 2025: € 570,944 ▲ 44% vs 2024 (€ 397,303) Unchanged	▲ 44%
Retained profit	€ 166,475 Retained profit 2022: € 166,475 First fiscal year in the series	€ 387,761 Retained profit 2023: € 387,761 ▲ 133% vs 2022 (€ 166,475) Favourable step	€ 447,535 Retained profit 2024: € 447,535 ▲ 15% vs 2023 (€ 387,761) Favourable step	€ 496,100 Retained profit 2025: € 496,100 ▲ 11% vs 2024 (€ 447,535) Favourable step	▲ 11%
Bank debt	€ 86,778 Bank debt 2022: € 86,778 First fiscal year in the series	€ 328,403 Bank debt 2023: € 328,403 ▲ 278% vs 2022 (€ 86,778) Unfavourable step	€ 308,570 Bank debt 2024: € 308,570 ▼ 6% vs 2023 (€ 328,403) Favourable step	€ 445,459 Bank debt 2025: € 445,459 ▲ 44% vs 2024 (€ 308,570) Unfavourable step	▲ 44%
Balance sheet total	€ 1,136,121 Balance sheet total 2022: € 1,136,121 First fiscal year in the series	€ 1,408,435 Balance sheet total 2023: € 1,408,435 ▲ 24% vs 2022 (€ 1,136,121) Unchanged	€ 1,386,053 Balance sheet total 2024: € 1,386,053 ▼ 2% vs 2023 (€ 1,408,435) Unchanged	€ 1,647,671 Balance sheet total 2025: € 1,647,671 ▲ 19% vs 2024 (€ 1,386,053) Unchanged	▲ 19%

Key figures of JD Pharma, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to JD Pharma?

What happened at JD Pharma in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Aug 28, 2026 New annual accounts for financial year 2025: profit of € 48,565 (▼ 19% vs 2024). filed late Source: NBB ↗
Oct 5, 2015 New establishment in Kortrijk. KBO
Oct 5, 2015 Start of the company according to the CBE. KBO
2015 Julie Dieusaert became a director. NBB

In short

From € 33,557 profit in 2022 to € 48,565 profit in 2025.

Paid € 126,285 in corporate taxes since 2022.

Best year ever: 2023, with € 221,286 profit.

Original PDFs at the National Bank ↗

Management

Julie Dieusaert

JD Pharma

Dieusaert Pattou bvba 50%

Behind JD Pharma is Julie Dieusaert. It owns 50% of Dieusaert Pattou bvba itself.

Directors

According to the 2025 annual accounts

Julie Dieusaert

Director

since 2015

Establishments

Establishment units

Physical locations of this company

Registered office

Overleiestraat(Kor) 52

8500 Kortrijk

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.

All companies at this address →

KORWIJT

€ 144,672 gross margin · 2025

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0639.894.746

VAT number

BE 0639.894.746

Registered office

Overleiestraat(Kor) 52, 8500 Kortrijk

Names & denominations

JD Pharma

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

5 October 2015

Peppol

Active · Active since 22 May 2025

Activities · NACE

Activiteiten van holdings

Holdings

Verhuur en exploitatie van eigen of geleased niet-residentieel onroerend goed, exclusief terreinen

Verhuur en exploitatie van eigen of geleased residentieel onroerend goed, exclusief sociale woningen

Overige zakelijke dienstverlening, neg

View on CBE Public ↗ Annual accounts (NBB) ↗

JD Pharma

Warning lights

Financials

What happened to JD Pharma?

Management

Directors

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions